Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type 2 Diabetics Clear all
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

NCT04595370
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease
Interventions
AZD9977, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 130 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00050479
View directory record Official record
Conditions
Macular Degeneration
Interventions
Celecoxib (Celebrex)
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients

NCT02008942
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
3
States / cities
Miami, Florida • Lenexa, Kansas • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 24, 2026, 4:45 PM EDT
Terminated Not applicable Interventional

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

NCT02541838
View directory record Official record
Conditions
Diabetes Complications, Diabetic Neuropathies
Interventions
Muscle power, balance perturbation, aerobic exercise
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
55 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Sep 24, 2026, 4:45 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

NCT02229175
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 24, 2026, 4:45 PM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

NCT00601250
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

NCT00638313
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04603629
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Sep 24, 2026, 4:45 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 4:45 PM EDT
Terminated Phase 1 Interventional Results available

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877
View directory record Official record
Conditions
Type 2 Diabetic Nephropathy
Interventions
PF-03882845, Spironolactone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2013 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Early Phase 1 Interventional Results available

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

NCT05081583
View directory record Official record
Conditions
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Interventions
Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

NCT00734253
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Pyridoxamine Dihydrochloride, Placebo
Drug
Lead sponsor
NephroGenex, Inc.
Industry
Eligibility
25 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

NCT02151461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Low Metformin, Metformin, Mid Metformin, High Metformin
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Chino, California • Palm Beach, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin

NCT00269061
View directory record Official record
Conditions
Non-Insulin-Dependent Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Sep 24, 2026, 4:45 PM EDT
Not listed Not applicable Interventional

Prospective, Multicenter, RCT of the Tenex Ultrasound System

NCT06137222
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Tenex TXB MicroTip Ultrasound system plus SOC, Standard of Care for diabetic foot ulcer
Device · Other
Lead sponsor
Tenex Health Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Mobile, Alabama • St. George, Utah
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

NCT05514548
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
INV-202, Placebo
Drug
Lead sponsor
Inversago Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Garden Grove, California • Pomona, California • Salinas, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

A Study of Mouth Rinses in Type 1 and Type 2 Diabetic Participants

NCT04449952
View directory record Official record
Conditions
Gingivits in Diabetics
Interventions
Listerine Cool Mint, 5% Hydroalcohol Mouth Rinse, Colgate Cavity Protection Toothpaste, Alcohol-Free Essential Oil Containing (AFEO) Mouth Rinse Lead Formula, Concept Curve Winter Series Toothbrush, Listerine Cool Mint Floss
Other · Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

NCT00551538
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lispro mix 75/25, Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 24, 2026, 4:45 PM EDT
Terminated Phase 2 Interventional

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

NCT00330200
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ISIS 113715
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 24, 2026, 4:45 PM EDT
Withdrawn Phase 4 Interventional

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

NCT00906529
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Levemir (Detemir) and Novolog (Aspart) Insulin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 24, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01358929
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO6807952
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Chula Vista, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 24, 2026, 4:45 PM EDT
Completed No phase listed Observational Results available

Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

NCT05530356
View directory record Official record
Conditions
Type 2 Diabetes, Diabetes Type 2, Diabetic Nephropathies, Nephropathy, Obesity, Adolescent Obesity, Diabetic Kidney Disease
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Dextran 40, Renal Biopsy, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 26 Years
Enrollment
57 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 24, 2026, 4:45 PM EDT